The stock is now trading near the $17.00 acquisition price, so the primary remaining catalyst is the closing of the Zymeworks deal, expected in H2 2026. Monitor for shareholder vote date and any regulatory conditions. The CVR component provides a speculative tail on ampreloxetine development by Zymeworks.
Drugs in focus
TBPH drug pipeline →YUPELRI
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially marketed (FDA approved November 2018; China NMPA approved June 2025).
- Next catalyst
- None dated
What to watchYUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 10 $16.91entry
- T+1 · 3mo ago +0.06%α +0.38% · $16.92
- T+5 · 3mo ago +0.06%α +0.11% · $16.92
- T+20 · 2mo ago +0.89%α +1.80% · $17.06
- T+60 · due 14d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theravance Biopharma reported Q2 2026 earnings with no analyst consensus provided for the current period. The filing is dominated by the pending acquisition by Zymeworks for $17.00 per share in cash plus a CVR, expected to close in H2 2026. YUPELRI collaboration revenue grew 11% YoY to $20.7M, and the company posted a GAAP net loss of $5.9M vs net income of $54.8M in Q2 2025 (which included a $75.1M one-time gain). Non-GAAP net income from operations was $9.5M vs a loss of $4.2M a year ago.
Key Financial Metrics
Key Facts
- Pending acquisition by Zymeworks at $17.00 per share in cash plus a CVR entitling shareholders to 80% of future ampreloxetine monetization proceeds over 10 years.
- YUPELRI collaboration revenue increased 11% year-over-year to $20.7 million in Q2 2026.
- GAAP net loss of $5.9 million in Q2 2026 vs net income of $54.8 million in Q2 2025 (which included a $75.1M net gain on realized royalty assets).
- Non-GAAP net income from operations was $9.5 million in Q2 2026 vs a non-GAAP net loss of $4.2 million in Q2 2025.
- Cash, cash equivalents and marketable securities totaled $387.7 million with no debt as of June 30, 2026.
- Operating expenses (excluding restructuring and transaction costs) decreased 35% year-over-year.
- Restructuring on track to deliver ~$60-70 million of annualized cash flow starting H2 2026.
Financial Impact
Zymeworks acquisition at $17.00 per share cash represents a fixed premium over the pre-announcement trading price, plus a CVR for potential additional value from ampreloxetine. YUPELRI revenue grew 11% YoY to $20.7M. Cash position is $387.7M with no debt.
Risk Factors
- Transaction may not close or may be delayed if shareholder approval or regulatory conditions are not met.
- CVR value is uncertain and depends entirely on Zymeworks' ability to monetize ampreloxetine within 10 years.
- GAAP net loss continued in Q2 2026 ($5.9M), though restructuring is expected to deliver positive annualized cash flow by H2 2026.
- TRELEGY milestone payment of $100 million depends on GSK achieving ~$3.5B in 2026 global net sales, not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093066 |
| Document: tm2622638d1_8k.htm | 0001104659-26-093066 |
| Document: 0001104659-26-093066-index-headers.html | 0001104659-26-093066 |
| Document: 0001104659-26-093066-index.html | 0001104659-26-093066 |
| Document: 0001104659-26-093066.txt | 0001104659-26-093066 |
| 8-K Data (Synthetic) | 0001104659-26-093066 |
Track record
12 reports on TBPH
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
- Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
- Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
- Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
- Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
- Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Viewing Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers